Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Buys $97,580.00 in Stock

Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Paul Josephs bought 17,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The shares were acquired at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the chief executive officer now directly owns 559,717 shares in the company, valued at $3,212,775.58. The trade was a 3.13 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Lifecore Biomedical Stock Performance

Shares of NASDAQ LFCR opened at $6.29 on Friday. The company has a debt-to-equity ratio of 12.90, a current ratio of 1.83 and a quick ratio of 0.80. The firm has a market cap of $232.89 million, a price-to-earnings ratio of 78.63 and a beta of 0.98. The stock’s fifty day moving average price is $7.05 and its two-hundred day moving average price is $5.82. Lifecore Biomedical, Inc. has a one year low of $3.68 and a one year high of $8.90.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings results on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%. On average, equities analysts forecast that Lifecore Biomedical, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

LFCR has been the topic of several research reports. Craig Hallum upped their price objective on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 22nd. Stephens reissued an “equal weight” rating and issued a $6.00 price target on shares of Lifecore Biomedical in a report on Friday, January 3rd.

Institutional Investors Weigh In On Lifecore Biomedical

Several institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp acquired a new position in Lifecore Biomedical in the 2nd quarter valued at $327,000. Rhumbline Advisers increased its position in shares of Lifecore Biomedical by 1,668.5% in the second quarter. Rhumbline Advisers now owns 26,899 shares of the company’s stock worth $138,000 after purchasing an additional 25,378 shares during the period. Renaissance Technologies LLC acquired a new position in Lifecore Biomedical in the second quarter valued at about $56,000. DCF Advisers LLC grew its stake in Lifecore Biomedical by 2.1% during the second quarter. DCF Advisers LLC now owns 290,684 shares of the company’s stock worth $1,491,000 after buying an additional 6,000 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in Lifecore Biomedical by 87.3% in the 2nd quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock valued at $1,540,000 after buying an additional 139,887 shares during the period. 83.36% of the stock is currently owned by institutional investors.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.